Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOXO-783 in Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation
NCT05307705Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- May 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 1, randomised, open-label trial of LOXO-783 in breast cancer and solid tumor (7 arms), sponsored by Eli Lilly and Company. Primary endpoints: Dose-Limiting Toxicities at 28 days and Dose-Limiting Toxicity-equivalent toxicities at 28 days. Started May 2022; status: active, not recruiting.
02
Drugs
LOXO-783
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05307705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05307705.